More News

6 July 2022

BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies

5 July 2022

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

5 July 2022

EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement

5 July 2022

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

2 July 2022

Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets

29 June 2022

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

27 June 2022

Ipsen to acquire Epizyme, expanding its portfolio in oncology

24 June 2022

invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs

23 June 2022

Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT

22 June 2022

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

16 June 2022

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

15 June 2022

Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

15 June 2022

Boehringer Ingelheim signs Option to Acquire Trutino Biosciences

14 June 2022

D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly

14 June 2022

Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

13 June 2022

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

10 June 2022

Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

8 June 2022

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

6 June 2022

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

3 June 2022

Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company

3 June 2022

Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies

3 June 2022

Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders

2 June 2022

Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

2 June 2022

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

1 June 2022

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

31 May 2022

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

24 May 2022

KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses

23 May 2022

Innoviva to Acquire Entasis Therapeutics

20 May 2022

Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review

19 May 2022

Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Her3-Targeted Immunotherapy Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

CD40 Agonists & CD40/L Antagonists Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

c-Met-Targeted Antibody Therapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

PSMA-Targeted Therapy Pipeline Review